Ilomedin

Iloprost trometamol, the active ingredient in Ilomedin, is a prostacyclin analog presented as an injection solution for intravenous use. It treats pulmonary arterial hypertension, digital ulcers associated with systemic sclerosis, and peripheral vasospasm, and is indicated for patients with severe disease where oral therapies are insufficient.

GNH USA supplies Ilomedin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance. The company provides full documentation, cold‑chain logistics, and post‑market support for all customers.

Ilomedin, a prostacyclin analog, is used to manage diseases characterized by vascular constriction and platelet activation.

- Pulmonary arterial hypertension: improves exercise capacity and reduces pulmonary vascular resistance. - Digital ulcers associated with systemic sclerosis: promotes ulcer healing and reduces new ulcer formation. - Peripheral vasospasm: alleviates vasospastic episodes and improves peripheral blood flow.

Ilomedin may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Flushing: warm sensation and redness of the skin. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Jaw pain: discomfort in the mandibular area.

Serious or Rare Side Effects: - Hypotension: significant drop in blood pressure requiring medical intervention. - Pulmonary edema: accumulation of fluid in the lungs. - Severe bleeding: uncontrolled hemorrhage due to platelet inhibition.

Before initiating Ilomedin therapy, several precautions should be considered to ensure patient safety.

- Contraindication: avoid use in patients with known hypersensitivity to iloprost or any component of the formulation. - Cardiovascular monitoring: observe blood pressure and heart rate during infusion, especially in patients with existing hypotension. - Bleeding risk: assess for active bleeding or anticoagulant therapy, as iloprost can impair platelet function. - Pregnancy and lactation: use only if potential benefit justifies potential risk; discuss with a specialist. - Renal impairment: adjust monitoring in patients with severe renal dysfunction due to altered drug clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ilomedin can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): combined use may cause severe hypotension. - Endothelin receptor antagonists (e.g., bosentan): additive vasodilatory effect increasing risk of low blood pressure.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin, heparin): enhanced antiplatelet effect may increase bleeding risk. - Calcium channel blockers (e.g., amlodipine): may potentiate vasodilation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may affect renal function and blood pressure control.